Welcome to Awesome Blog Design perfect blog
Business, Healthcare

Legend Biotech announces Phase 1b/2 study data of cilta-cel, an investigational BCMA CAR-T, showing early, deep, and durable responses in heavily pretreated patients with multiple myeloma

Combined Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 Annual Meeting show 97 percent overall response rate and 12-month progression free survival rate of 77 percent at median follow up of 12.4 months SOMERSET, N.J.–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”),